Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
25%(1 trials)

Phase Distribution

Ph early_phase_1
1
20%
Ph phase_4
2
40%
Ph not_applicable
1
20%
Ph phase_2
1
20%

Phase Distribution

1

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution5 total trials
Early Phase 1First-in-human
1(20.0%)
Phase 2Efficacy & side effects
1(20.0%)
Phase 4Post-market surveillance
2(40.0%)
N/ANon-phased studies
1(20.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(4)
Other(1)

Detailed Status

Completed4
unknown1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (20.0%)
Phase 21 (20.0%)
Phase 42 (40.0%)
N/A1 (20.0%)

Trials by Status

unknown120%
completed480%

Recent Activity

0 active trials
Showing 5 of 5
unknownearly_phase_1

The Neuroprotective Effect of PEG-GCSF in the Traumatic Optic Neuropathy

NCT06168188
completednot_applicable

Aranesp and Neulasta in Patients With Sarcoma Receiving Adriamycin and Ifosfamide

NCT00283621
completedphase_2

Dose-Finding Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

NCT01648322
completedphase_4

A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer

NCT00277160
completedphase_4

Neulasta® in Subjects With Advanced Non-Small-Cell Lung Cancer (NSCLC) During Chemotherapy

NCT00115206

Clinical Trials (5)

Showing 5 of 5 trials
NCT06168188Early Phase 1

The Neuroprotective Effect of PEG-GCSF in the Traumatic Optic Neuropathy

Unknown
NCT00283621Not Applicable

Aranesp and Neulasta in Patients With Sarcoma Receiving Adriamycin and Ifosfamide

Completed
NCT01648322Phase 2

Dose-Finding Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

Completed
NCT00277160Phase 4

A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer

Completed
NCT00115206Phase 4

Neulasta® in Subjects With Advanced Non-Small-Cell Lung Cancer (NSCLC) During Chemotherapy

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5